VDR Agonist Prevents Diabetic Endothelial Dysfunction through Inhibition of Prolyl Isomerase-1-Mediated Mitochondrial Oxidative Stress and Inflammation

• Published in: Oxidative medicine and cellular longevity Vol. 2018; no. 2018; pp. 1 - 13
• Main Authors: Peng, Feng, Chai, Dajun, Xu, Chang-Sheng, Lin, Liming, Zhang, Meijin, Lin, Jinxiu
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 01.01.2018; Hindawi; John Wiley & Sons, Inc
• Subjects: Agonists; Animals; Apoptosis; Atherosclerosis; Blood coagulation factors; Coronary vessels; Cytokines; Dextrose; Diabetes; Diabetes Mellitus, Experimental - pathology; Disease Models, Animal; Endocrinology; Endothelium; Endothelium, Vascular - pathology; Enzymes; Ethylenediaminetetraacetic acid; Experiments; Glucose; Humans; Inflammation; Inflammation - drug therapy; Inflammation - pathology; Laboratory animals; Male; Metabolism; Metabolites; Mice; Mitochondria - drug effects; Nitric oxide; Oxidative stress; Oxidative Stress - drug effects; Peptidylprolyl Isomerase - antagonists & inhibitors; Phosphorylation; Physiology; Proteins; Receptors, Calcitriol - therapeutic use; Rodents; Transfection; Vitamin D; Vitamin deficiency; China

Background and aim. Upregulation of prolyl isomerase-1 (Pin1) protein expression and activity was associated with the pathogenesis of diabetic vasculopathy through induction of endothelial oxidative stress and inflammation. Moreover, VDR agonist protects against high glucose-induced endothelial apop...